IMCR
Immunocore Holdings PLC - ADR

513
Mkt Cap
$1.64B
Volume
550,996.00
52W High
$40.71
52W Low
$23.15
PE Ratio
-45.59
IMCR Fundamentals
Price
$32.30
Prev Close
$32.04
Open
$31.56
50D MA
$33.61
Beta
0.71
Avg. Volume
518,814.30
EPS (Annual)
-$0.707
P/B
4.32
Rev/Employee
$765,173.26
$1,320.03
Loading...
Loading...
News
all
press releases
Immunocore (NASDAQ:IMCR) Downgraded by Zacks Research to "Hold"
Zacks Research cut Immunocore from a "strong-buy" rating to a "hold" rating in a research note on Wednesday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Immunocore (NASDAQ:IMCR) Given New $75.00 Price Target at Needham & Company LLC
Needham & Company LLC boosted their target price on shares of Immunocore from $71.00 to $75.00 and gave the company a "buy" rating in a report on Thursday...
MarketBeat·4d ago
News Placeholder
Immunocore Q4 Earnings Call Highlights
Immunocore (NASDAQ:IMCR) executives highlighted continued commercial momentum for KIMMTRAK and progress across a diversified pipeline during the company's fourth-quarter and full-year 2025 earnings...
MarketBeat·5d ago
News Placeholder
Immunocore (NASDAQ:IMCR) Announces Earnings Results
Immunocore (NASDAQ:IMCR - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·5d ago
News Placeholder
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
Jazz Pharmaceuticals beats Q4 earnings and revenue estimates as neuroscience and oncology sales climb, sending shares up 5% in after hours.
Zacks·5d ago
News Placeholder
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
Zacks·5d ago
News Placeholder
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
RGEN tops Q4 EPS estimates as revenues jump 18% Y/Y, with solid organic growth and stronger margins heading into 2026.
Zacks·5d ago
News Placeholder
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
Zacks·5d ago
News Placeholder
Insider Selling: Immunocore (NASDAQ:IMCR) Insider Sells 5,965 Shares of Stock
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) insider David Berman sold 5,965 shares of Immunocore stock in a transaction on Wednesday, February 18th. The shares were sold at...
MarketBeat·10d ago
News Placeholder
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Zacks·10d ago
<
1
2
...
>

Latest IMCR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.